Sign In
Buy MBX
$48.40
+2.01 (+4.33%)
At Close: Jun 24, 2026
MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows Market
05:10pm, Monday, 22'nd Sep 2025
MBX Biosciences surged after canvuparatide's Phase 2 data showed strong efficacy and safety in hypoparathyroidism, addressing a significant unmet need. MBX's lead candidate outperformed placebo and co
MBX Biosciences Announces Proposed Public Offering
04:14pm, Monday, 22'nd Sep 2025
CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide the
MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise
09:32am, Monday, 22'nd Sep 2025
Shares of MBX Biosciences catapulted Monday after the company posted promising results for its experimental thyroid disease treatment.
Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE)
CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide the
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity
08:00am, Thursday, 04'th Sep 2025
Preclinical data support the potential for improved weight loss and tolerability with once-monthly administration of MBX 4291 Preclinical data support the potential for improved weight loss and tolera
